Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Charli E. Harlow"'
Autor:
Charli E. Harlow, Josan Gandawijaya, Rosemary A. Bamford, Emily-Rose Martin, Andrew R. Wood, Peter J. van der Most, Toshiko Tanaka, Hampton L. Leonard, Amy S. Etheridge, Federico Innocenti, Robin N. Beaumont, Jessica Tyrrell, Mike A. Nalls, Eleanor M. Simonsick, Pranav S. Garimella, Eric J. Shiroma, Niek Verweij, Peter van der Meer, Ron T. Gansevoort, Harold Snieder, Paul J. Gallins, Dereje D. Jima, Fred Wright, Yi-hui Zhou, Luigi Ferrucci, Stefania Bandinelli, Dena G. Hernandez, Pim van der Harst, Vickas V. Patel, Dawn M. Waterworth, Audrey Y. Chu, Asami Oguro-Ando, Timothy M. Frayling
Publikováno v:
American Journal of Human Genetics, 109(9), 1638-1652. CELL PRESS
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are currently under clinical development for treating anemia in chronic kidney disease (CKD), but it is important to monitor their cardiovascular safety. Genetic variants can be used a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea5af52c8198d180333920474519e29d
https://research.rug.nl/en/publications/dbc76815-e070-4ba9-801d-e653aebb2f58
https://research.rug.nl/en/publications/dbc76815-e070-4ba9-801d-e653aebb2f58
Autor:
Charli E Harlow, Vickas V Patel, Dawn M Waterworth, Andrew R Wood, Robin N Beaumont, Katherine S Ruth, Jessica Tyrrell, Asami Oguro-Ando, Audrey Y Chu, Timothy M Frayling
Publikováno v:
Human molecular genetics.
Prolyl hydroxylase (PHD) inhibitors are in clinical development for anaemia in chronic kidney disease. Epidemiological studies have reported conflicting results regarding safety of long-term therapeutic haemoglobin (Hgb) rises through PHD inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12672b8b214116fea85a4dc0e62003e1
https://pubmed.ncbi.nlm.nih.gov/36048866
https://pubmed.ncbi.nlm.nih.gov/36048866